semaglutide masld 📘 AASLD adds to practice guidance: Key updates The AASLD has updated its MASLD practice guidance to formally include semaglutide as a treatment option for adults with MASH and F2–F3 MASLD Pharmacotherapy: Current Standards, Emerging

PBM timelines are generally faster than payer-managed PA because PBM systems are more standardized and more electronically integrated

CBD doesnt bind directly to CB1 or CB2 receptors but influences them indirectly, supporting the bodys natural processes.* CB1 receptors are particularly important for sleep regulation, as they influence neural activity and circadian rhythms

A nutrient-dense plan designed to support GLP-1 medications by focusing on protein, healthy fats, fiber, and whole foods, promoting better health outcomes and reducing side effects

Key takeaways Nearly 3 in 4 UK GLP-1 users have felt more confident since starting the medication

Semaglutide also improved critical modifiable CV risk factors, including SBP, DBP, LDL, and HDL, suggesting pleiotropic mechanisms beyond glycemic control

Eur J Clin Investig 45:12341242